Randomized, double-blind, placebo-controlled, parallel-group phase IIA study to evaluate the efficacy and safety of PF-06651600 and PF06700841 by mouth as induction and open-label extension therapy in patients with moderate or severe Crohn's disease
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Developer: PFIZER INC.
- Phase: II
- Execution start: 27/06/2018
- End of execution: 28/02/2021
- IP: MARIA JOSE CABELLO TAPIA